

Patent claims

1. Use of at least one effector of glutathione metabolism together with α -lipoic acid, its salts and/or its pro-drugs for the simultaneous, separate or timed cytoprotective treatment of chronically obstructive lung diseases.
5
2. Use according to claim 1,
10 characterised in that the dose of the α -lipoic acid, its salts and/or its pro-drugs for administration to a human patient is between 30 and 1800 mg/d, preferably between 200 and 600 mg/d.
15
3. Use according to at least one of the preceding claims,
characterised in that ambroxol of the general formula I,
20

I

Br

NH₂

Br

CH₂—NH·····Cyclohexyl—OH

- its salts and/or its pro-drugs is/are used as the effector.
25
4. Use according to claim 3,
characterised in that the dose of ambroxol, its salts and/or its pro-drugs for administration to a human patient is between 7.5 and 90 mg/d, preferably between 60 and 75 mg/d.

5. Use according to at least one of the preceding claims, **characterised in that** silibinin, its salts and/or its pro-drugs is/are used as the effector.
- 5 6. Use according to claim 5, **characterised in that** the dose of silibinin, its salts/or its pro-drugs for administration to a human patient is between 20 and 1600 mg/d, preferably between 300 and 800 mg/d.
- 10 7. Use according to at least one of the preceding claims, **characterised in that** the medicine can be administered by inhalation, orally or parenterally.
- 15 8. Use according to at least one of the preceding claims, **characterised in that** the medicine contains further additives selected from the group of aqueous solvents, stabilisers, suspending, dispersing and wetting agents.
- 20 9. Use according to at least one of the preceding claims, **characterised in that** the medicine is presented in the form of an aerosol, a solution, granules, a powder, an emulsion, a tablet and/or a film tablet.
- 25 10. Use according to at least one of the preceding claims, **characterised in that** the effector of glutathione metabolism and the α -lipoic acid, its salts and/or

its pro-drugs are presented in a single formulation.

11. Use according to at least one of the preceding
5 claims,

characterised in that the effector of glutathione metabolism and the α -lipoic acid, its salts and/or its pro-drugs are presented in separate formulations.